In line with these data, recent analysis of the TransATAC clinical trial cohort (Afentakis et al, 2013) and retrospective (Gee et al, 2010) studies in ER+ early breast cancer treated with hormonal therapy but not chemotherapy, show that expression of BAG-1 significantly associates with that of ER and PgR, and correlates with tumour grade. This evidence concerns the gene BAG1 and breast carcinoma.